GT Biopharma Inc (GTBP) Stock Price, Quote & News

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

kim46 Mar. 17 at 1:10 PM

$GTBP $IBRX Hell yeah! Own 25,000+ and constantly adding. This drug hunts them down

0 · Reply

Investerare_SAAB Mar. 13 at 7:29 PM

$GTBP next lovely one $SAFX

0 · Reply

Kaynoshi Mar. 13 at 11:32 AM

$GTBP word on the street is this is the next $IBRX ?

1 · Reply

Investing4Knowledge Mar. 11 at 3:15 PM

$GTBP - crazy oversold now. Loading heavy here 💰

0 · Reply

topstockalerts Mar. 9 at 8:29 PM

After Hours Top Gainers PT2 $VFF $EEIQ $BWEN $VERA $GTBP

1 · Reply

SwingTrades1 Mar. 5 at 11:00 PM

$GTBP Using first-generation TriKE data as a guide, we can monitor higher-dose cohort results and potentially avoid reaching the maximum dose, which could shorten the transition into Phase 2.

1 · Reply

Dr_Monkeybreath Mar. 5 at 6:22 PM

$SLRX 👀 $GTBP data any day. 🧨

0 · Reply

OfficialStocktwitsUser Mar. 3 at 2:11 PM

$GTBP RSI: 46.86, MACD: -0.0494 Vol: 0.03, MA20: 0.48, MA50: 0.64 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

lucasbrennan902 Mar. 3 at 9:16 AM

$GTBP

0 · Reply

harrijakey Mar. 3 at 9:05 AM

$GTBP

0 · Reply

GT Biopharma Reports Full Year 2025 Financial Results

Feb 17, 2026, 7:30 AM EST - 4 weeks ago

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

Feb 3, 2026, 8:30 AM EST - 6 weeks ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

Jan 15, 2026, 8:30 AM EST - 2 months ago

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Jan 15, 2026, 8:01 AM EST - 2 months ago

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

Dec 19, 2025, 7:44 AM EST - 3 months ago

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Nov 19, 2025, 8:00 AM EST - 4 months ago

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

Nov 14, 2025, 9:00 AM EST - 4 months ago

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:05 PM EDT - 7 months ago

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 7 months ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Jun 13, 2025, 9:00 AM EDT - 9 months ago

GT Biopharma Appoints New Member to its Board of Directors

May 19, 2025, 9:00 AM EDT - 10 months ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Feb 25, 2025, 2:00 PM EST - 1 year ago

GT Biopharma Announces Exercise of Warrants

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

May 15, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 26, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 1, 2024, 11:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

May 15, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023, 9:05 AM EDT - 3 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

Mar 30, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 9:00 AM EST - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Jun 10, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

May 16, 2022, 8:01 AM EDT - 4 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 12, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

Apr 11, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

kim46 Mar. 17 at 1:10 PM

$GTBP $IBRX Hell yeah! Own 25,000+ and constantly adding. This drug hunts them down

0 · Reply

Investerare_SAAB Mar. 13 at 7:29 PM

$GTBP next lovely one $SAFX

0 · Reply

Kaynoshi Mar. 13 at 11:32 AM

$GTBP word on the street is this is the next $IBRX ?

1 · Reply

Investing4Knowledge Mar. 11 at 3:15 PM

$GTBP - crazy oversold now. Loading heavy here 💰

0 · Reply

topstockalerts Mar. 9 at 8:29 PM

After Hours Top Gainers PT2 $VFF $EEIQ $BWEN $VERA $GTBP

1 · Reply

SwingTrades1 Mar. 5 at 11:00 PM

$GTBP Using first-generation TriKE data as a guide, we can monitor higher-dose cohort results and potentially avoid reaching the maximum dose, which could shorten the transition into Phase 2.

1 · Reply

Dr_Monkeybreath Mar. 5 at 6:22 PM

$SLRX 👀 $GTBP data any day. 🧨

0 · Reply

OfficialStocktwitsUser Mar. 3 at 2:11 PM

0 · Reply

lucasbrennan902 Mar. 3 at 9:16 AM

$GTBP

0 · Reply

harrijakey Mar. 3 at 9:05 AM

$GTBP

0 · Reply

SwingTrades1 Mar. 2 at 4:42 PM

$GTBP Overall, GT Biopharma’s balance sheet has materially improved from 2024 to 2025 in terms of: ✔ Greater assets and cash, ✔ Reduced liabilities, and ✔ Positive equity versus a deficit previously. All we need now is data.

0 · Reply

StocktwitsEarnings Mar. 2 at 2:35 PM

$GTBP Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $2.22 up 233.73% YoY • GT Biopharma anticipates its unaudited proforma cash balance of approximately $9M as of January 31, 2026, will provide sufficient cash runway through Q4 2026.

0 · Reply